FRET Assay for CRBN Affinity Measurement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack efficient and scalable assays to measure the affinity between compounds and cereblon (CRBN) and identify new CRBN-binding therapeutic compounds, which is crucial for developing drugs with improved efficacy and toxicity profiles, especially in cancer treatment.
Innovation Solution
A complex comprising CRBN with a europium-anti-His antibody and a Cy5-conjugated small molecule that binds to CRBN, using fluorescence resonance energy transfer (FRET) to determine compound binding and affinity, allowing for the identification of potential therapeutic compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional affinity measurement methods are used, then the assay can measure compound binding to CRBN, but the method lacks sensitivity and high-throughput capability
Solution Approach 1:
The patent replaces traditional mechanical/chemical affinity measurement methods with a fluorescence resonance energy transfer (FRET) optical system. The FRET assay uses fluorescent donor and acceptor molecules that transfer energy when in close proximity, enabling sensitive and automated detection of compound binding to CRBN without complex mechanical operations.
Solution Approach 2:
The patent changes the measurement parameter from traditional binding assays to fluorescence intensity ratios. By monitoring the ratio of acceptor to donor fluorescence emission, the system achieves both high sensitivity and automated high-throughput capability, transforming the detection parameter to enable scalable screening.
2Productivity
If no standardized assay is available, then various methods can be used to study CRBN interactions, but there is a lack of efficient and scalable measurement capability
Solution Approach 1:
The patent creates a universal FRET-based assay platform that can screen multiple compounds against CRBN using the same standardized protocol. The assay uses a common CRBN complex preparation method and fluorescent probe system that can be applied across different compound libraries, enabling scalable and consistent measurement of binding affinities.
Solution Approach 2:
The patent introduces a standardized CRBN complex as an intermediary between the compound library and the detection system. This complex, containing CRBN bound to specific ligands and fluorescent probes, serves as a consistent mediator that enables reliable and scalable measurement of compound interactions across high-throughput screening.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a sensitive and high-throughput assay to measure the affinity of compounds to CRBN, enabling the identification of new small molecules with high affinity and potential therapeutic effects, thereby facilitating the development of more effective cancer treatments.
Implementation Method 1
using fluorescence resonance energy transfer (FRET) to determine compound binding and affinity
Data Source
AI summary
A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.